The struggling local biotech that manufactures and markets products for use in biopharmaceutical manufacturing, diagnostics and animal reproduction, has been placed under receivership while under voluntary administration. Despite the recent improvements in the companies performance and position due to restructuring and focusing, sales expectations have failed to eventuate. It is an unfortunate conclusion to the company’s downfall but one that is not uncommon to the global biotech industry.
- Minimizing risk in health technology innovation: A checklist shar.es/1F3xpu 2 days ago
- Gender tokenism and bias prevail in biotech boardrooms dx.doi.org/10.1038/nbt031… 1 month ago
- Science journalism can be evidence-based, compelling — and wrong nature.com/news/science-j… 1 month ago
- s.hbr.org/2lYPvg8 1 month ago
- Starting companies on post-harvest tech: How Hazel Technologies keeps fresh fruit and vegetables from spoiling tcrn.ch/2lPaO2M 1 month ago